Core Insights - Ant Group's AI health application "Ant Aifu" has rapidly climbed to the 3rd position in the Apple App Store download rankings following its new version release [1] - The domestic AI healthcare sector has seen continuous advancements in policy, technology, products, and applications this year [1] - Technological breakthroughs are expected to transition from individual products to a full-chain scenario, with application scenarios moving from large hospitals to grassroots and individual levels [1] Industry Trends - AI healthcare demonstrates significant application value in enhancing medical device functionality, interpreting test results, assisting clinical decision-making, and health management [1] - Medical enterprises and hospitals must prioritize AI healthcare as an innovative direction and competitive trend [1] - With ongoing national policies and industry technology catalyzing developments, the application scenarios for AI healthcare are expected to accelerate [1]

人民财讯12月22日电，中信建投研报称，蚂蚁集团旗下AI健康应用"蚂蚁阿福"新版App发布后，下载量 迅速攀升，位居苹果应用商店下载总榜的第3位。今年以来，国内AI医疗在政策、技术、产品及应用等 方面均有持续进展，技术突破有望从单个产品走向场景全链条，应用场景从大医院下沉到基层和个体。 AI医疗在提升医疗器械功能、检查检验结果解读、辅助临床医生决策、健康管理等多个领域的应用价 值较大，是医疗企业和医院必须重视的创新方向和竞争趋势。在国家政策和行业技术的持续催化下， AI医疗应用场景有望加速落地，建议关注行业投资机会。 转自：证券时报 ...

丨证券研究报告丨 行业研究丨点评报告丨软件与服务 [Table_Title] 蚂蚁阿福验证赛道高景气，医疗或将成为原 生 AI 垂类应用突破点 报告要点 [Table_Summary] 12 月 15 日，蚂蚁集团正式宣布旗下 AI 健康应用"AQ"完成品牌升级，全新命名为"蚂蚁阿 福"，目前月活跃用户已经达到 1500 万，稳居健康管理类 AI 应用首位。当前时点，医疗信息 化正从 B 端建设迈向 C 端价值再造的新阶段，放眼全球，AI+Healthcare 也是巨头重点投资方 向， AI 医疗有望成为 AI 垂类应用破局点，建议重点关注具备场景卡位优势与技术落地能力的 医疗信息化龙头。 分析师及联系人 [Table_Author] SAC：S0490520030004 SFC：BUX668 宗建树 刘思缘 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 软件与服务 cjzqdt11111 [Table_Title 蚂蚁阿福验证赛道高景气，医疗或将成为原生 2] AI 垂类应用突破点 [Table_Summary2] 事件描述 12 月 15 日，蚂蚁集团正式 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

行 业 研 究 医药生物 2025 年 12 月 21 日 医药生物 1 AI 医疗应用商业化加速，重视 AI 医疗底部机会 投资要点： 行 业 定 期 报 告 行情回顾：本周（2025 年 12 月 15 日- 2025 年 12 月 19 日）中信医药指数 下跌 0.1%，跑赢沪深 300 指数 0.2 pct，在中信一级行业分类中排名第 22 位； 2025 年初至今中信医药生物板块指数上涨 15.5%，跑输沪深 300 指数 0.6 pct， 在中信行业分类中排名第 16 位。本周涨幅前五的个股为：华人健康（+ 55.9%）、 鹭燕医药（+ 36.8%）、漱玉平民（+ 35.7%）、美年健康（+ 24.1%）、康众医 疗（+ 21.2%）。 AI 医疗商业化加速，底部掘金正当时：1）AI 医疗刚需体现：最新上线 "蚂蚁阿福"流量凸显 AI 医疗应用真实需求，智谱港股聆讯意味着资本 加速认证新阶段；医疗大模型突破式演变，医疗机构大规模参与，截至 2025 年 5 月第三方榜单中国内排名前 100 的医院已全部完善大模型部署，多科 室应用全场景辅助治疗型 AI。2）商业化加速实质性落地：相关公司加速 推出 ...

[Table_Tag] [Table_Summary] 观点 ◼ 泛 AI 分支低位方向：AI 医疗、端侧、智能驾驶、具身智能 ➢ AI 医疗 AI 大模型在病理检测、制药等医药领域具备深度应用潜力。AI+病理检测 有助于提升诊疗效率、减少漏诊误诊，核心痛点在于医疗高质量数据集的 建立与数据壁垒的打通。11 月国家卫健委发布《关于促进和规范"人工智 能+医疗卫生"应用发展的实施意见》，提出到 2027 年建立一批行业高质 量数据集和可信数据空间，形成一批优秀的专病专科垂直大模型和应用， 加强 AI 模型在智能诊疗、智能康复、传染病监测等领域的应用。近期阿里 系医疗模型蚂蚁阿福冲上 IOS 应用商店排行前三，体现出 C 端对于借助专 业模型实现"普惠医疗"与即时健康服务的核心诉求，后续医疗大模型端 伴随数据集深化与应用模式创新有望出现更多爆款。此外，AI 模型在制药 领域的渗透有望显著降低药物发现的成本与时间周期，加速靶点开发与验 证过程，同时通过模拟临床试验降低失败风险，亦是 AI 医疗中长期重要 产业趋势。 ➢ AI 端侧 证券研究报告·策略报告·策略周评 策略周评 20251221 商业航天与核聚变之后， ...

报 海外地缘政治风险；产品研发失败的风险；集采进一步扩容，导致药品、器 械等降价压力提升的风险；行业竞争激烈导致价格下降的风险；原材料成本 大幅上涨的风险。 行 行业周报 业 全国医疗保障工作会议召开，部署 2026 年重点工作 | | | | | | ——医药生物行业周报 | | | | | 研 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | SAC NO： | 分析师： | 侯雅楠 | S1150524120001 | 月 | 年 2025 | 12 | 21 | 日 | | 究 | | | 医药生物 | | | | | | | | | | | | | 投资要点： | | | | | | | | | | | 证券分析师 | 行业要闻 | | | | | | | | | | | |  | | | | | | | | | | 担当作为 | 侯雅楠 | （1）积极进取 | | 全力推进医保高质量发展——全国医疗保障工作会 | | | | | | | | | houyn@bhzq.com | 议在京召开； | | | ...

Group 1 - The article discusses the launch of Ant Group's AI health assistant "Ant Aifu," which aims to transform low-frequency medical consultations into high-frequency health management through an "AI companionship" model, achieving a digital closed-loop in healthcare, pharmaceuticals, and insurance [3][4]. - The application has reportedly surpassed 15 million monthly active users (MAU) and has reached the top of the app store rankings, indicating strong user engagement and market penetration [4]. - The integration of Ant Group's underlying payment and insurance infrastructure enhances the service's capability, allowing for a seamless transition from consultation to medication purchase and claims processing [4]. Group 2 - The report on Zhi Zi Cheng Technology (9911.HK) highlights its successful product and national replication strategy, with projected revenues of 6.9 billion, 8.41 billion, and 9.7 billion RMB for 2025-2027, and net profits of 950 million, 1.24 billion, and 1.49 billion RMB respectively, leading to a "buy" rating with a target price of 14.5 HKD [8]. - Salt Lake Pharmaceutical (300181.SZ) plans to acquire a variety of trace element injection assets, which is expected to enhance its product structure and profitability, with projected net profits of 655 million, 836 million, and 1.063 billion RMB for 2025-2027, maintaining a "buy" rating [24]. - The report on Fen Zhong Media (002027.SZ) indicates a stable business performance driven by strong demand from internet clients, with revised net profit forecasts of 5.62 billion, 6.05 billion, and 6.47 billion RMB for 2025-2027, maintaining an "overweight" rating [30].

S1130525060003 gantanhuan gjzq.com.cn AI + + 投资逻辑 本周蚂蚁阿福 APP 上市后高流量带动下医疗 AI 主题关注度较高。此前互联网医疗痛点来自于 1）远程平台客户粘性 不足，活跃用户比例较低；2）优质医疗资源有限。而蚂蚁阿福从 AI 工具到 AI 朋友全面升级，并上线健康陪伴、健 康问答、健康服务三大功能。健康陪伴功能通过高频健康管理的方式很好的解决了此前客户粘性问题，同时也成为链 接患者与药品、终端服务的入口。此外平台，链接了全国 5000 家医院和 30 万真人医生，拥有六位国家院士领衔的全 国 500 多位名医开设的'AI 分身'，实现优质医疗资源"平民化"。我们认为蚂蚁阿福是 AI 医疗规模化市场与可行商 业模式再验证，同时平台流量有望为"医+药+险"全链条赋能。 药品板块：12 月 18 日，武田宣布其 TYK2 抑制剂 Zasocitinib 针对中重度斑块状银屑病的 2 项注册 III 期临床中达 到所有主要与次要终点。第 16 周时 ZASO 组超过一半患者实现 PASI 90，平均约 30%患者实现 PASI 100。武田制药计 划在即将举行的 ...

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 流量入口的重定向，推动高频医疗健康交互 "阿福"通过AI降低了健康咨询门槛，过去互联网医疗的痛点是"低频"，而"AI陪伴"将医疗拉向了高频健康管 理，成为链接患者与药品、服务的入口。我们认为阿福AI 陪伴模式有望显著提升用户活跃度（DAU）与留存 率。AI 能够在用户需求产生的早期阶段完成精准识别与分流，为后端的高毛利药品销售及专业医疗服务实现 高效导流。 赋能"医+药+险"全链路闭环。蚂蚁依托支付生态（医保电子凭证）、保险（好医保）与阿福的AI能力结合， 实现了从"产生症状"到"AI咨询"再到"在线购药/挂号"的无缝对接。我们认为这种全链路的无缝对接，显著降低 了跨环节的交易摩擦成本。对于用户而言，实现了"医+药+险"的一站 ...